Waldenström Macroglobulinemia Excellence Forum

Waldenström Macroglobulinemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Managing Peripheral Neuropathies Associated With Waldenström Macroglobulinemia

11/02/2022

Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.

Norman Latov, MD, outlines the...

11/02/2022

Oncology

Videos

Do All Patients Diagnosed With Waldenström Macroglobulinemia Require Immediate Intervention?

11/02/2022

Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.

Morie Gertz, MD, discusses...

11/02/2022

Oncology

Videos

Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM

12/16/2021

Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...

Steven P. Treon, MD, MA, PhD,...

12/16/2021

Oncology

Videos

Michael Wang, MD, Talks LOXO-305 for MCL, WM

12/07/2020

In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.

In this video, Dr Wang discusses...

12/07/2020

Oncology

Podcasts

Episode 2: BTK Inhibitors for CLL and Lymphomas

07/03/2020

On this episode of Blood Bytes, John Leonard, MD, and Richard Furman, MD, discuss BTK inhibitors for the treatment of CLL and lymphomas.

On this episode of Blood Bytes,...

07/03/2020

Oncology

Debates and Roundtables

BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

06/05/2020

An international panel of experts compare and discuss the 3 different BTK inhibitors active in the treatment of Waldenström macroglobulinemia.

An international panel of...

06/05/2020

Oncology

BLOOD BYTES

Episode 1: Maintenance Rituximab for Waldenström Macroglobulinemia

04/24/2020

Steven Treon, MD, PhD, and Christian Buske, MD, discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.

Steven Treon, MD, PhD, and...

04/24/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology